Celine Gisbert, MD
Obesity Medicine · Pensacola, FLNPI 1831216969
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Novo Nordisk at 58.4% of the total. Reporting peaked in 2019 at $722 and has fallen 85.8% since, to $103 in 2025.
Across 54 payments — averaging $25.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$789
- Lilly USA, LLC$111
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$67
- Takeda Pharmaceuticals U.S.A., Inc.$57
- Pfizer$49
- GSK$42
- plus $236 from 10 others
What the payments were for
- Consulting fees$91%
- Food & beverage$1,34299%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $789 |
| Lilly USA, LLC | 4 | $111 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $57 |
| Pfizer | 4 | $49 |
| GSK | 3 | $42 |
| Abbott | 2 | $39 |
| Shire North American Group Inc | 2 | $32 |
| Amgen | 2 | $27 |
| AbbVie | 2 | $27 |
| Nalpropion Pharmaceuticals LLC | 2 | $24 |
| Endo Pharmaceuticals Inc. | 1 | $24 |
| Kvk-tech, Inc. | 5 | $22 |
| AstraZeneca | 1 | $17 |
| Merck | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,351 in reported general payments places this provider in the 75th percentile of 21 obesity medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 459 | $503,587 |
| MounjaroTirzepatide | 260 | $278,178 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $83,334 |
| EliquisApixaban | 66 | $68,883 |
| JardianceEmpagliflozin | 31 | $52,840 |
| MyrbetriqMirabegron | 46 | $45,158 |
| LinzessLinaclotide | 28 | $40,514 |
| TrulicityDulaglutide | 34 | $37,184 |
| JanuviaSitagliptin Phosphate | 25 | $28,345 |
| XareltoRivaroxaban | 19 | $28,133 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $15,367 |
| CreonLipase/Protease/Amylase | 12 | $14,814 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $11,166 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $8,504 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $6,852 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $789 | $503,587459 claims |
| Lilly USA, LLCMounjaro, Trulicity | $111 | $315,362294 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $42 | $94,500107 claims |
| PfizerEliquis | $49 | $68,88366 claims |
| AbbVieLinzess, Creon | $27 | $55,32940 claims |
| MerckJanuvia | $12 | $28,34525 claims |
| Johnson & JohnsonXarelto | $12 | $28,13319 claims |
| AstraZenecaBrilinta | $17 | $6,18113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 21 obesity medicine providers in Florida.
Other obesity medicine in Pensacola
- Lisa FerreiraWesley Chapel$183K
- Jawan Ayer ColeTampa$85K
- Bharti ShetyeTampa$21K
- Dauris FiguerasWeston$7K
- Casey BonaquistJacksonville$1K
- Grettel Rodriguez GarciaVero Beach$553
- Kelley LangTallahassee$362
- Marci MannaPunta Gorda$353
- Lindsay WilesTampa$327
- Cynthia LarimerGainesville$245
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.